Results 121 to 130 of about 17,592 (206)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Cancer Medicine
Introduction Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the current standard of care for first‐line (1L) treatment of hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR ...
Adam M. Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth Karanth, Benjamin Li, Elizabeth Esterberg, Doris Makari, Sean D. Candrilli, Ravi K. Goyal, Hope S. Rugo   +10 more
doaj   +1 more source

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors

Pharmaceutics
Background/Objectives: Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or refractory brain tumors ...
John C. Panetta, Nicholas S. Selvo, David Van Mater, Clinton F. Stewart   +3 more
doaj   +1 more source

Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth

, 2019
Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge ...
Cheng-Lung Hsu, Angel Chao, Chyong-Huey Lai, Li-Yu Lee, Chia-Lung Tsai, Tzu-Hao Wang, Chiao-Yun Lin   +6 more
core   +1 more source

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity

Cancer Management and Research, 2018
Daniel J Asby,1 Clare L Killick-Cole,1 Lisa J Boulter,1 William GB Singleton,1,2 Claire A Asby,3 Marcella J Wyatt,1 Neil U Barua,1,2 Alison S Bienemann,1 Steven S Gill1,2 1Functional Neurosurgery Research Group, Translational Health Sciences, Bristol ...
Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WGB, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS   +8 more
doaj  

A COMBINATION OF PALBOCICLIB AND RADIOTHERAPY IMPROVES SURVIVAL IN GLIOBLASTOMA

, 2016
A COMBINATION OF PALBOCICLIB AND RADIOTHERAPY IMPROVES SURVIVAL IN ...
Swapna Joshi (1814116), Mustafa Khasraw (13078896), Kerrie McDonald (6794915)   +2 more
core  

Palbociclib as an Antitumor Drug: A License to Kill

Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase are the CDK4 and CDK6 kinases, which are controlled by D-type cyclins.
Federica Cossu, Agnieszka Łupicka-Słowik, Marcin Sieńczyk   +2 more
core   +1 more source

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study. [PDF]

ESMO Open
Schmidt M, Thill M, Rey J, Rautenberg B, Bjelic-Radisic V, Decker T, Rom J, Kögel M, Lübbe K, Nacke A, Seiler S, Just M, Müller V, Buss-Steidle R, Terhaag J, Mundhenke C, Denkert C, Holtschmidt J, Loibl S.   +18 more
europepmc   +1 more source

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor‐positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition.
Gierliński, Marek, Peltier, Julien, Härtlova, Anetta, Trost, Matthias, Miettinen, Teemu P., Jansen, Valerie M., Björklund, Mikael   +6 more
core   +1 more source

Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India. [PDF]

PLoS One
Mukherjee A, Goyal P, Tripathi R, Goyal S, Batra U, Talwar V, Goel V, Jain A, Saha S, Bothra S, Agrawal C, Chugh S, Doval DC.   +12 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source